This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations And Business Development

NEW YORK, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has appointed JP Benya Vice President, Commercial Operations and Business Development, effective September 24, 2012.

With over twenty years of marketing and operational experience in the pharmaceutical industry, Mr. Benya has developed and implemented strategies and tactical programs for both primary care and specialty products in the U.S. and globally. He joins Ventrus from pharmaMARK, a boutique healthcare consulting company with clients including Amgen, Lilly, Pfizer and Merck, where he was a Principal since 2008. From 2006 to 2007, Mr. Benya was Vice President, Marketing, for Transcept Pharmaceuticals. Prior to Transcept, he held various positions at Sanofi-Synthelabo from 1999 to 2005, where he developed commercial, marketing and reimbursement strategies for various primary care and specialty products. While at Sanofi, he led, among other accomplishments, a doubling of sales, to $1.5Bn, for the insomnia medication Ambien® (zolpidem).  Prior to Sanofi, he was at Schering-Plough from 1991 to 1999, where he spearheaded the successful sales growth of Intron® A and Rebetron™, among other specialty pharmaceutical products. Mr. Benya is an Adjunct Professor of Marketing at Columbia Business School, serves as a Guest Lecturer at New York University Stern School of Business and Montclair State University School of Business, and is a member of the Editorial Advisory Board of the International Journal of Pharmaceutical & Healthcare Marketing. Mr. Benya graduated from Brown University, and earned an MBA in Marketing and Finance from Columbia University.

"JP's expertise is ideally suited to our commercial goals, including our reimbursement strategy and focused launch strategy for VEN 307,  as we complete its development and move forward toward commercialization," said Russell H. Ellison, M.D., M.Sc., Chairman and Chief Executive Officer of Ventrus Biosciences, Inc. "His record of success with both specialty and primary care products also gives us great confidence that our strategies will allow us to realize the full potential for VEN 307 to replace compounded diltiazem and become a treatment of choice for anal fissures."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.44 -0.95%
GOOG $692.33 -0.84%
TSLA $232.32 -3.92%
YHOO $36.02 -1.40%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs